cyrilzakka/clinical-trials huggingface dataset:
Neurobiological Effects of Oxytocin in Schizophrenia - Imaging Study

To investigate whether 24IU oxytocin can result in changes in functional brain connectivity in patients with schizophrenia and healthy individuals using functional magnetic resonance imaging (fMRI). The study will also examine the effect of oxytocin receptor gene polymorphism on the functional connectivity


Eligibility Criteria:
Inclusion and Exclusion Criteria:

Schizophrenia subjects:

Inclusion criteria 1) Males between 18 and 50 years 2) Diagnosis of DSM-IV schizophrenia, schizoaffective or schizophreniform disorder 3) capacity to provide informed consent, as evaluated by the MacArthur Competence Assessment Tool for Clinical Research Exclusion criteria

1. General impairment in intellectual functioning
2. History of alcohol or substance dependence in the last 12 months (with the exception of nicotine)
3. Contraindication to oxytocin like hypersensitivity, vascular disease, chronic nephritis, epilepsy, asthma
4. Past history of head injury resulting in loss of consciousness or neurosurgery
5. Concomitant severe medical conditions
6. Metal implants or paramagnetic objects within the body or claustrophobia which may interfere with the MRI.

Healthy volunteers:

Inclusion criteria

1. Males between 18 and 50 years
2. Capacity to provide informed consent Exclusion criteria

1) Life-time diagnosis of psychiatric illnesses including substance abuse 2) General impairment in intellectual functioning 3) Past history of head injury resulting in loss of consciousness or neurosurgery 4) Concomitant severe medical or neurological conditions 5) Metal implants or paramagnetic objects or claustrophobia 6) Family history of schizophrenia, schizoaffective or schizophreniform disorder in family member (sibling, parent or offspring) 7) Contraindication to oxytocin like hypersensitivity, vascular disease, chronic nephritis, epilepsy, asthma.
Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients

In newly diagnosed Hodgkin lymphoma patients, pre-treatment Beta-2 Microglobulin (B2M) levels will be measured. A thorough baseline assessment will be performed using CT imaging, and tumor tissue samples will be collected for Immunohistochemical (IHC) analysis to quantify CD8+ cell infiltration. Patients will be closely monitored throughout their treatment, with a follow-up CT scan at the end of therapy to evaluate therapeutic response. This study aims to investigate the correlation between pre-treatment B2M levels and CD8+ immune cell infiltration in tumor tissues, assessing their potential as predictive markers for chemotherapy response.


Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed patients with Hodgkin lymphoma
* No prior history of malignancy
* Absence of primary or secondary immunodeficiencies

Exclusion Criteria:

* Patients who have previously undergone treatment
* Patients with acute or chronic infections
* Patients with renal disorders
* Individuals with autoimmune diseases
* HIV-positive patients
Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar

A cross-sectional study of urogenital schistosomiasis and sexually transmitted infections (STI) prevalence and associated morbidity in a rural community in Madagascar. Clearance of infections and resolution of morbidity were subsequently studied in two phases following systematic anti-STI and anti-schistosoma treatment, respectively.

The study was conducted in the Schistosoma haematobium high-endemic SIRAMA sugarcane plantation near the Ambilobe town in the northern province of Diego Suarez in Madagascar. A neighboring low-endemic village, Mataipako, was selected a control village. Participants aged 15 to 49 years old from SIRAMA were included in the study if positive for S.haematobium egg in urine.

A questionnaire addressing previous medical history and current urogenital symptoms was applied. A physical examination, including ultrasonophical (US) examination of urinary tract by transabdominal route, was undertaken. A pelvic examination, including transvaginal US was performed in women. In men, the prostate and the seminal vesicles were examined by transrectal US.

The following sexually transmitted infections (STI) were systematically assessed:

* Neisseria gonorrheae
* Chlamydia trachomatis
* Mycoplasma genitalium
* Trichomonas
* Treponema pallidum
* Herpes simplex 1 and 2

After baseline assessment, all participants (and partners) were systematically treated with an anti-STI regimen according to the existing guidelines by the Ministry of Health in Madagascar.

Re-assessment by questionnaire, physical examination and sampling for STIs was undertaken 4 weeks later followed by systematic praziquantel treatment to general community, including study participants.

A final follow-up study following the baseline protocol was conducted 5 months later.

Eligibility Criteria:
Inclusion Criteria:

* adults
* positive Schistosoma haematobium egg excretion in urine
* signed written consensus

Exclusion Criteria:

* children
* negative Schistosoma haematobium egg excretion in urine
A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as the colon) in patients with a history of colorectal adenomas.


Eligibility Criteria:
Inclusion Criteria:

* Eligible patients must have undergone a complete colonoscopy within 12 weeks of study entry with removal of all polyps; at least one polyp must have been confirmed a large bowel pre-cancerous polyp (adenoma) by the study pathologist.

Exclusion Criteria:

* History with a specific hereditary large bowel polyp syndrome
* History of a large bowel adenoma before age 35
* Small or large bowel resection or history of inflammatory bowel disease
* History of cancer within the five years before enrollment
* Expected need for chronic NSAID therapy
* Positive test result for stool occult blood
* Uncontrolled hypertension, stroke or temporary mini stroke (TIA) within the past 2 years, angina or congestive heart failure with symptoms that occur at rest or with minimal activity
* History of myocardial infarction (heart attack), coronary angioplasty, or coronary artery bypass grafting within the past 1 year
* Pregnancy
Toremifene in Treating Patients With Ovarian Cancer

RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using toremifene may fight ovarian cancer by reducing the production of estrogen.

PURPOSE: Randomized phase II trial to study the effectiveness of toremifene in treating patients who have recurrent or refractory ovarian cancer.

OBJECTIVES:

* Determine the effects of toremifene in terms of response rate, duration of response, duration of survival, and toxicity in patients with chemotherapy resistant papillary carcinoma of the ovary.
* Assess whether a dose response effect is likely for this regimen in these patients.
* Assess quality of life of these patients.

OUTLINE: This is a randomized study.

Patients receive one of two doses of oral toremifene daily for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed before therapy and then every 4 weeks during therapy.

Patients are followed every 12 weeks until death.

PROJECTED ACCRUAL: The study was closed before any patient accrual.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed serous papillary carcinoma of the ovary

  * Recurrent or refractory disease following at least one regimen including paclitaxel, cisplatin, or carboplatin
* Measurable disease outside of irradiated field
* No CNS metastases

PATIENT CHARACTERISTICS:

Age:

* 18 and over

Performance status:

* Zubrod 0-2

Life expectancy:

* At least 16 weeks

Hematopoietic:

* Absolute neutrophil count at least 1,800/mm\^3
* Platelet count at least 125,000/mm\^3
* No history of thrombosis or thromboembolic events

Hepatic:

* Bilirubin no greater than 2.0 mg/dL

Renal:

* Creatinine no greater than 2.0 mg/dL

Other:

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 2 months after study
* No other concurrent second malignancy or prior malignancy within past 5 years, except basal or squamous cell skin cancer or curatively treated stage I carcinoma of the cervix
* No concurrent infection
* At least 3 days since prior fever (unless due to tumor)
* No other concurrent severe medical illness
* No HIV positivity

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* See Disease Characteristics
* No concurrent chemotherapy

Endocrine therapy:

* No prior tamoxifen or antiestrogen therapy

Radiotherapy:

* See Disease Characteristics
* At least 6 months since prior radiotherapy
* No concurrent radiotherapy except to symptomatic or potentially disabling bone lesion accompanied by other measurable disease

Surgery:

* Not specified

Other:

* No concurrent anticoagulants
* No other concurrent therapeutic trials
Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.

To advance current knowledge on the vascular contributions to dementia

This is a multi-center study at Washington University (WASH U), University of Southern California (USC), and Huntington Medical Research Institute (HMRI).The overall goal of both the AA program and the PPG program is to advance current knowledge on the vascular contributions to dementia particularly in individuals with the major genetic risk factor for late-onset AD, i.e., apolipoprotein E-ε4 (APOE4) gene that develop early vascular dysfunction and significant cerebrovascular pathology compared to non-carriers, and establish whether the neurovasculature plays a key role in cognitive decline, and therefore is a key new therapeutic target to treat dementia in APOE4 carriers.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, any race
* Age \> 18 years
* Participation in one of the ongoing projects affiliated with the Knight ADRC at Washington University and referred by the MAP staff and a Washington University physician.
* Normal cognition or early-stage symptomatic AD
* Females of childbearing potential without documented history of menopause or hysterectomy who do participate must not be pregnant or breastfeeding at screening
* (negative urine β-HCG within 24 hours prior to injection), and must agree to avoid becoming pregnant. Females of childbearing potential who do not agree to use reliable contraception or refrain from sexual activity for 24 hours following administration of flortaucipir injection.
* Enrollment in DCE-MRI study
* Capacity to give informed consent and follow study procedures

Exclusion Criteria:

* Any illness preventing cooperation with testing or longitudinal participation
* Exclusion from the Knight ADRC or DIAN referring project
* Has a high risk for Torsades de Pointes or is taking medications known to prolong or may prolong QT interval (refer to study attachment "Restricted Medication List").
* MRI contraindications (e.g. electronic medical devices, severe claustrophobia, inability to lie still for long periods) that make it unsafe to participate in an MRI scan, using standard screening processes implemented by Washington University and Barnes-Jewish Hospital
* Currently pregnant or breastfeeding
Histopathological Examination of Iris Tissue in Buphthalmos

To revise the etiology of the primary congenital glaucoma in some infants.

Combined trabeculotomy trabeculectomy with mitomycin C was done in 11 eyes. Histopathological examination of the peripheral iris tissue specimen was done in all cases.

Eligibility Criteria:
Inclusion Criteria:

* infants under age of 2 years
* 1ery glaucoma

Exclusion Criteria:

* infants more than 2 years
* 2ery glaucoma
* previous glaucoma surgery
SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)

Assessment of the seroprevalence and sero-incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Nursing Home (NH) residents and staff in Belgium.

In this longitudinal cohort study, 3036, nursing home (NH) residents (1656) and staff (1380), spread over 69 nursing homes throughout Belgium will be repeatedly sampled at a 2-month interval. Seroprevalence and -incidence will be assessed by means of a point-of-care rapid antibody test with additional collection of a Dry Blood Spot sample for quantitative detection of immune markers\*. Sample collection (capillary blood samples) at baseline (day 0, week 0) will start in a staggered way, so all baseline samples among the different nursing homes are collected within the first 21 days after collection of the first sample. Follow-up sample collection will occur with a 2-month interval in week 8, week 16, week 24, week 32 and week 40 after the baseline collection of that specific nursing home. At each timepoint, questionnaires will be taken concerning medical history, clinical outcomes and potential COVID-19 riskfactors. The recruited NHs will be equally spread across the Belgian territory according to geographic and demographic characteristics to guarantee general representativity. Forty-four participants (20 staff, 24 residents) will be randomly included per nursing home. (\* collection of the Dry Blood Spot is part of a sub-study by Ghent University)

Eligibility Criteria:
Inclusion Criteria:

* residents and staff from Belgian nursing homes

Exclusion Criteria:

* service flat residents
* temporary staff, employed for a period of less then 1 year starting from baseline collection
Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions

In children treated for intracranial lesions, the 2 factors of the obesity are : the location of the lesion (hypothalamic-pituitary region) and craniopharyngiomas

Approximately 80 % of the hypothalamic-pituitary lesions that occur in children are craniopharyngiomas with one or three cases per 1 million children each year.

One major problem remains unsolved : the obesity

This study is performed to optimize the management of the children with hypothalamic-pituitary lesions by reducing the hyperinsulinemia due to the lesion and the surgery

Eligibility Criteria:
Inclusion Criteria:

* Age 6 to 18 years
* Obesity with body mass index \> 97 percentile or \> 2 SD
* Hypothalamic-pituitary lesions not evolutive
* Hyperinsulinemia defined by insulin peak after oral glucose tolerance test\>100 UI/L
* Absence of diabetes mellitus defined by basal plasma glucose \< 1.2 g/L and glucose peak after oral glucose tolerance test \< 2 g/L and HbA1c \< 7 %
* Hormonal replacement therapy stable from at least three months excluding the treatment of diabetes insipidus which can be adjusted
* Normal plasma thyroxine
* Written informed consent of the children and the parents

Exclusion Criteria:

* evolutive lesion
* recent surgery or radiotherapy (\< 6 months)
* modification of hormonal replacement therapy during the three previous months
* diabetes mellitus defined by basal plasma glucose \> 1.2 g/L and glucose peak after oral glucose tolerance test \> 2 g/L and HbA1c \> 7 %
* renal or hepatic failure
* uncontrolled hypertension
* hypersensitivity to benzothiazine drugs
* pregnancy
* difficulties to understand the protocol
Strenght Training in Osteoporosis Prevention

The study involves 120 women over the age of 50.

All participants in the study take part in high-intensity strength training for 10 months.

In addition, half of the participants receive vitamin D3 at a dose of 4,000 IU/day.

The investigators hypothesize that training combined with vitamin D3 supplementation will be more effective in preventing osteoporosis than training alone.


Eligibility Criteria:
Inclusion Criteria:

* age over 50
* female

Exclusion Criteria:

* ongoing cancer,
* unstabilized cardiovascular disease,
* cognitive disorders,
* radiological treatment in the last 12 months,
* other contraindications to undertaking high-intensity strength training,
* diseases affecting the skeleton such as: Paget's disease, type I diabetes mellitus,
* taking medications affecting skeletal conditions including: long-term therapy with corticosteroids, thiazides, antiretroviral drugs,
* contraindications to taking vitamin D including: hypercalcemia, nephrolithiasis, sarcoidosis, lack of cholecalciferol hydroxylase activity in the liver and kidneys.
Bacillus Subtilis in Parkinson's Disease

The aim of this study is to evaluate whether the administration of Bacillus Subtilis influences gut and blood biomarkers relevant to the proposed mechanism(s) of action, as well as being acceptable as a regular supplement for people with Parkinson's disease.

Following informed consent, participants will undergo screening. If eligible, they will be invited to attend a baseline visit (week 0) to complete clinical assessments and provide a faecal and blood sample before starting their assigned intervention. Each participant will be randomised 1:1 to visually identical capsules containing either Bacillus Subtilis or placebo to be taken for 24 weeks. Telephone follow-up will be performed at week 8 to ensure compliance and answer any participant questions. Repeat clinical assessments and faecal/blood sample collection will take place at weeks 24 (treatment end date) and 36 (to assess longevity of biomarker changes after the intervention has stopped). Faecal samples will be collected at home within seven days prior to the clinic visits and brought to the appointment. Microbiota composition in faecal samples and blood biomarkers will be analysed in participant samples. Motor and non-motor symptom rating scales will also be administered.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of Parkinson's disease
* Able to provide written informed consent
* Over 50 years old
* Motor symptom duration over 12 months
* Stable dopaminergic medication regime for at least 3 months

Exclusion Criteria:

* Use of probiotic supplements and probiotic-fortified foods (such as probiotic drinks and yoghurts) within past 3 months
* Use of antibiotics within past 3 months
* Previous gastrointestinal surgery or chronic organic bowel disorder
* History of clinically significant motor fluctuations
* History of postural instability or falls
* Current smoker
* Known or suspected allergy to probiotics
* Regular use of antacids, proton pump inhibitors, laxatives or anti-diarrheal drugs
* Use of hypoglycaemic or diabetes drugs
* Participation in clinical trial of investigational medicinal product within past 3 months
* Co-morbidities or other factors that, in the opinion of the investigator, make the patient unlikely to comply with study protocol
Normal Values for 3D High Resolution Anorectal Manometry in Children

Anorectal 3D high resolution manometry (3D HRM) is the most advanced version of manometry equipment and has been recently introduced into clinical practice. It is the most precise method to assess the anal sphincter pressure function and may be crucial for planning and controlling surgical procedures of the anorectal area. Normal values in pediatric population have not been established.

The aim of this study is complex evaluation of anorectal function in children without symptoms from lower GI tract and establishment of normal values.


Eligibility Criteria:
Inclusion Criteria:

* parental agreement
* age: 1 to 18 yr

Exclusion Criteria:

* parental disagreement
* children younger than 1 yr
* children after the surgery for anorectal malformations
* children with constipation during the last 10 months
* children with nonretentive fecal soiling
* children with inflammatory bowel diseases or any other type of large bowel inflammation
* children with anal fissure, anal varices, inflammation of the anorectal area or any other disease that may interfere with function of anorectum
Follow Up Study of Tear in the Rotator Culf

Rotator culf tears are common in the aging population and are a significant morbidity source. The common knowledge is that the major tears do not heal and constantly expanding.Still since the majority of the patients are old the acceptable therapy is conservative treatment.

Our objective is to estimate the accuracy of rotator culf tear utilizing an ultrasound.


Eligibility Criteria:
Inclusion Criteria:

* Was diagnosed with shoulder tear
* Size of the tear till 2.5 cm
* The opposite tendon-normal

Exclusion Criteria:

* systematic Diseases .
* Injury to the shoulder after the previous US.
* Pregnancy
Transdiagnostic Oncology Program in Primary Care

The goal of this observational study is to learn about how cancer survivors experience a relatively new 12-month interdisciplinary aftercare program called the Transdiagnostic Oncologic Program (TOP). TOP is an innovative program offered as part of routine family-doctor care among several practices in the province Drenthe, the Netherlands. It is coordinated by the family doctor and caried out by an interdisciplinary team, consisting of the family doctor, a physiotherapist, nutritionist, and optionally a psychologist. The main questions this study aims to answer are:

* Is TOP feasible and acceptable?
* Does TOP lead to improvements in quality of life in cancer survivors? Patients who were eligible for the program (n=54) were asked to participate in research as well. Everyone who participated in TOP (n=19) agreed to participate in this study as well. Those who declined participation (n=35), were asked to serve as controls, of which 16 agreed to do so.


Eligibility Criteria:
Eligibility criteria for the program and for the study were the same, with the exception that participants were willing to sign informed consent to participate in the study.

Inclusion criteria:

* being between ≥18 and ≤ 75 years old
* having been diagnosed with cancer at least 6 months ago and/or have been long-term stable.

Exclusion criteria:

* having severe physical risks due to cancer treatment and / or comorbidities
* currently undergoing intensive chemotherapy or other treatment
* having cognitive or psychosomatic complaints that interfere with successful participation
* having skin cancer, except for melanomas with metastasis
* having a life expectancy of \<1 year